Veritable L.P. Has $322,000 Stake in Antares Pharma, Inc. (ATRS)
Veritable L.P. reduced its position in Antares Pharma, Inc. (NASDAQ:ATRS) by 8.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 100,000 shares of the specialty pharmaceutical company’s stock after selling 9,500 shares during the period. Veritable L.P. owned about 0.06% of Antares Pharma worth $322,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in ATRS. Wells Fargo & Company MN increased its position in shares of Antares Pharma by 21.6% in the first quarter. Wells Fargo & Company MN now owns 767,600 shares of the specialty pharmaceutical company’s stock worth $2,180,000 after acquiring an additional 136,600 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Antares Pharma by 20.1% in the first quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock worth $476,000 after acquiring an additional 28,029 shares in the last quarter. M&T Bank Corp purchased a new position in shares of Antares Pharma in the first quarter worth approximately $227,000. California Public Employees Retirement System increased its position in shares of Antares Pharma by 14.4% in the first quarter. California Public Employees Retirement System now owns 934,300 shares of the specialty pharmaceutical company’s stock worth $2,653,000 after acquiring an additional 117,300 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Antares Pharma by 4.3% in the first quarter. Vanguard Group Inc. now owns 5,619,088 shares of the specialty pharmaceutical company’s stock worth $15,958,000 after acquiring an additional 232,349 shares in the last quarter. 36.77% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Veritable L.P. Has $322,000 Stake in Antares Pharma, Inc. (ATRS)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/05/veritable-l-p-has-322000-stake-in-antares-pharma-inc-atrs.html.
ATRS has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Antares Pharma in a research report on Friday, June 23rd. Chardan Capital initiated coverage on shares of Antares Pharma in a research report on Friday, June 23rd. They issued a “buy” rating and a $5.00 target price on the stock. Vetr downgraded shares of Antares Pharma from a “strong-buy” rating to a “buy” rating and set a $3.47 target price on the stock. in a research report on Monday, June 26th. Finally, Piper Jaffray Companies set a $4.00 target price on shares of Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $4.34.
Shares of Antares Pharma, Inc. (NASDAQ ATRS) opened at 3.86 on Thursday. The firm has a 50-day moving average of $3.10 and a 200 day moving average of $2.96. The company’s market capitalization is $603.73 million. Antares Pharma, Inc. has a 52-week low of $1.41 and a 52-week high of $3.93.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.01. The company had revenue of $13.42 million during the quarter, compared to analysts’ expectations of $12.99 million. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. On average, analysts anticipate that Antares Pharma, Inc. will post ($0.11) EPS for the current year.
Antares Pharma Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.